SCHEMBL1102610

SCHEMBL1102610

c1ccc(-p2c3ccccc3c3cc(-c4c5ccccc5c(-c5ccc6c(c5)c5ccccc5p6-c5ccccc5)c5cnccc45)ccc32)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 1/20 0.33
▸ ALOX5 P09917 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ TNF P01375 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ RAD52 P43351 1/20 0.31
▸ CYP11B1 P15538 1/20 0.31
▸ ACHE P22303 1/20 0.30
▸ GABRP O00591 1/20 0.30
▸ GABRD O14764 1/20 0.30
▸ IKBKB O14920 1/20 0.30
▸ AURKA O14965 1/20 0.30
▸ CHUK O15111 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ PIM1 P11309 1/20 0.30
▸ TOP1 P11387 1/20 0.30
▸ GABRA1 P14867 1/20 0.30
▸ IDO1 P14902 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12886825 0.83 CYP11B2 (0.36) MAPK10CYP11B1TDO2
SCHEMBL12887080 0.82 ALOX5 (0.31) ALOX5
SCHEMBL12886768 0.82 GRIN2D (0.32) ALOX5POLBCYP11B1
SCHEMBL12887166 0.82 CYP17A1 (0.35) MAPK10CYP11B1
SCHEMBL1103027 0.81 ALDH1A1 (0.31) KDM4EALDH1A1TOP1
SCHEMBL13158630 0.79 ESR1 (0.33) ACHE
SCHEMBL1103340 0.77 CDK4 (0.32) —
SCHEMBL13147529 0.77 ALDH1A1 (0.37) ALOX5ACHEALDH1A1HPGDMAOA
SCHEMBL1103633 0.76 MAPK10 (0.42) MAPK10ALOX5KDM4ETNFPOLB
SCHEMBL1102558 0.76 KDM4E (0.43) MAPK10KDM4ETNFPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MAPK10 1869/4885ALOX5 9/4885KDM4E 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback